LC-OCT Imaging for Basal Cell Carcinoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new imaging technique called LC-OCT to aid in planning surgery for basal cell carcinoma (BCC), a common type of skin cancer. The goal is to determine if this noninvasive imaging provides doctors with better information before performing Mohs surgery, a precise procedure for removing BCC. Suitable participants have BCC involving superficial layers and are already scheduled for Mohs surgery. As an unphased trial, this study offers patients the chance to contribute to innovative research that could enhance surgical outcomes for future BCC patients.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that LC-OCT imaging is safe for presurgical assessment?
Research has shown that LC-OCT imaging examines skin layers in detail without cutting the skin. It is primarily used to diagnose basal cell carcinoma (BCC), a common type of skin cancer.
Although studies do not specifically address the safety of LC-OCT, its noninvasive nature suggests low risk. No reports of harmful side effects exist, as it neither uses radiation nor involves surgery. This makes it a safe option for patients requiring a detailed skin examination.12345Why are researchers excited about this trial?
Researchers are excited about LC-OCT imaging for basal cell carcinoma because it offers a noninvasive way to assess the skin. Unlike traditional biopsies, which require removing a tissue sample, LC-OCT uses light to create detailed images of the skin layers, potentially providing a faster and pain-free diagnosis. This method could help doctors diagnose and monitor basal cell carcinoma more efficiently, reducing the need for invasive procedures and improving patient comfort.
What evidence suggests that LC-OCT imaging is effective for assessing basal cell carcinoma?
Research has shown that LC-OCT imaging, the focus of this trial, is a promising tool for diagnosing basal cell carcinoma (BCC), a common type of skin cancer. One study found that LC-OCT correctly identified BCC 87% of the time and correctly ruled it out 91% of the time, demonstrating its effectiveness in spotting BCC. Another study found that LC-OCT results matched traditional tissue study results 66.7% of the time for identifying different BCC types. Additionally, LC-OCT increased doctors' confidence in their diagnoses compared to standard exams. In some cases, it even identified BCC perfectly, with 100% accuracy, and ruled it out 98% of the time, highlighting its potential effectiveness.23567
Who Is on the Research Team?
Gyorgy Paragh, MD
Principal Investigator
Roswell Park
Are You a Good Fit for This Trial?
This trial is for individuals who are scheduled to undergo Mohs micrographic surgery for basal cell carcinoma (BCC), a common type of skin cancer. The study aims to include those who can provide informed consent and are available for follow-up.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging Procedure
Participants undergo noninvasive line field confocal optical coherence tomography (LC-OCT) imaging for presurgical assessment
Surgical Procedure
Participants undergo Mohs micrographic surgery for removal of basal cell carcinomas
Follow-up
Participants are monitored for safety and effectiveness after the imaging and surgical procedures
What Are the Treatments Tested in This Trial?
Interventions
- LC-OCT Imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor